ACHV RSI Chart
Last 7 days
8.5%
Last 30 days
9.4%
Last 90 days
15.7%
Trailing 12 Months
-30.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2016 | 19.7M | 17.8M | 11.1M | 5.1M |
2015 | 16.8M | 15.9M | 17.8M | 18.2M |
2014 | 36.5M | 35.1M | 30.1M | 27.1M |
2013 | 23.9M | 27.8M | 31.1M | 29.9M |
2012 | 5.6M | 6.2M | 11.6M | 20.1M |
2011 | 10.1M | 10.3M | 6.6M | 5.5M |
2010 | 0 | 21.6M | 17.6M | 13.6M |
2009 | 0 | 0 | 0 | 25.5M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 19, 2024 | jacobs cindy | acquired | - | - | 16,250 | president & cmo |
Apr 19, 2024 | jacobs cindy | sold (taxes) | -17,846 | 4.51 | -3,957 | president & cmo |
Apr 19, 2024 | wan jerry | acquired | - | - | 5,625 | principal accounting officer |
Apr 19, 2024 | wan jerry | sold (taxes) | -10,147 | 4.51 | -2,250 | principal accounting officer |
Apr 19, 2024 | stewart richard alistair | acquired | - | - | 22,500 | executive chairman |
Apr 19, 2024 | stewart richard alistair | sold (taxes) | -45,663 | 4.51 | -10,125 | executive chairman |
Apr 19, 2024 | bencich john | acquired | - | - | 25,000 | ceo |
Apr 19, 2024 | bencich john | sold (taxes) | -27,456 | 4.51 | -6,088 | ceo |
Mar 04, 2024 | stewart richard alistair | bought | 45,850 | 4.585 | 10,000 | executive chairman |
Mar 04, 2024 | bencich john | bought | 45,850 | 4.585 | 10,000 | ceo |
Which funds bought or sold ACHV recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | COMERICA BANK | unchanged | - | 1,062 | 11,362 | -% |
May 15, 2024 | Sofinnova Investments, Inc. | new | - | 6,900,360 | 6,900,360 | 0.38% |
May 15, 2024 | Nantahala Capital Management, LLC | new | - | 2,972,430 | 2,972,430 | 0.17% |
May 15, 2024 | Alyeska Investment Group, L.P. | new | - | 2,140,700 | 2,140,700 | 0.01% |
May 15, 2024 | J. Goldman & Co LP | reduced | -63.63 | -166,533 | 111,571 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | new | - | 880,085 | 880,085 | -% |
May 15, 2024 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | new | - | 23.00 | 23.00 | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | new | - | 100,981 | 100,981 | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | added | 15.86 | 3,107 | 14,280 | -% |
May 15, 2024 | STATE STREET CORP | reduced | -12.79 | -9,905 | 250,957 | -% |
Unveiling Achieve Life Sciences Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Achieve Life Sciences Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Achieve Life Sciences Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2016Q4 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 | 2015Q3 | 2015Q2 | 2015Q1 | 2014Q4 | 2014Q3 | 2014Q2 | 2014Q1 | 2013Q4 | 2013Q3 | 2013Q2 | 2013Q1 | 2012Q4 | 2012Q3 | 2012Q2 | 2012Q1 | 2011Q4 |
Revenue | - | - | - | 2,122,000 | 2,940,000 | 6,024,000 | 6,737,000 | 4,025,000 | 1,374,000 | 5,653,000 | 4,803,000 | 4,929,000 | 11,731,000 | 8,604,000 | 9,862,000 | 6,340,000 | 5,076,000 | 9,780,000 | 6,570,000 | 2,429,000 | 1,316,000 | 1,236,000 |
Operating Expenses | - | - | - | - | 7,372,000 | 9,503,000 | 11,428,000 | - | 6,371,000 | - | 12,045,000 | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 261.5% | 70.00 | 19.00 | 24.00 | 29.00 | 21.00 | 30.00 | 24.00 | 34.00 | 41.00 | 48.00 | 38.00 | 46.00 | 34.00 | 40.00 | 28.00 | 16.00 | 17.00 | 21.00 | 11.00 | 15.00 | 15.00 |
Current Assets | 298.7% | 68.00 | 17.00 | 22.00 | 26.00 | 18.00 | 27.00 | 21.00 | 31.00 | 38.00 | 45.00 | 35.00 | 42.00 | 30.00 | 37.00 | 24.00 | 13.00 | 13.00 | 17.00 | 8.00 | 11.00 | 11.00 |
Cash Equivalents | 328.4% | 66.00 | 16.00 | 20.00 | 25.00 | 17.00 | 25.00 | 18.00 | 29.00 | 36.00 | 43.00 | 33.00 | 42.00 | 30.00 | 36.00 | 22.00 | 12.00 | 12.00 | 17.00 | 7.00 | 10.00 | 7.00 |
Net PPE | -100.0% | - | 0.00 | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Goodwill | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | -1.2% | 21.00 | 21.00 | 20.00 | 19.00 | 20.00 | 22.00 | 23.00 | 21.00 | 19.00 | 19.00 | 3.00 | 5.00 | 4.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 4.00 |
Current Liabilities | -1.2% | 21.00 | 21.00 | 4.00 | 3.00 | 20.00 | 22.00 | 7.00 | 5.00 | 4.00 | 5.00 | 3.00 | 5.00 | 4.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 4.00 |
Long Term Debt | - | - | - | 16.00 | 16.00 | - | - | 16.00 | 15.00 | 15.00 | 15.00 | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Current | 2.9% | 17.00 | 17.00 | - | - | 16.00 | 16.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
LT Debt, Non Current | - | - | - | 16.00 | 16.00 | - | - | 16.00 | 15.00 | 15.00 | 15.00 | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | 3515.5% | 49.00 | -1.45 | 4.00 | 10.00 | 0.00 | 8.00 | 1.00 | 13.00 | 21.00 | 28.00 | 35.00 | 41.00 | 30.00 | 37.00 | 26.00 | 15.00 | 15.00 | 18.00 | 8.00 | 12.00 | 10.00 |
Retained Earnings | -3.9% | -172 | -165 | -160 | -153 | -144 | -135 | -124 | -111 | -101 | -93.59 | -86.43 | -79.70 | -68.43 | -60.43 | -55.71 | -51.95 | -49.02 | -45.70 | -42.51 | -38.84 | -31.29 |
Additional Paid-In Capital | 34.9% | 222 | 164 | 164 | 163 | 145 | 144 | 126 | 125 | 123 | 122 | 121 | 121 | 98.00 | 98.00 | 81.00 | 66.00 | 64.00 | 64.00 | 51.00 | 50.00 | 41.00 |
Shares Outstanding | 61.8% | 34.00 | 21.00 | 21.00 | 21.00 | 18.00 | 18.00 | 10.00 | 10.00 | 9.00 | 8.00 | 8.00 | 7.00 | 6.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 91.00 | - | - | - | 47.00 | - | - | - | 85.00 | - | - | - | 15.00 | - | - | - | 15.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -21.0% | -5,300 | -4,379 | -5,100 | -6,700 | -8,300 | -11,143 | -11,307 | -8,340 | -6,779 | -5,218 | -8,694 | -9,076 | -6,452 | -2,480 | -4,335 | -2,198 | -4,461 | -3,414 | -3,072 | -3,841 | -4,889 |
Share Based Compensation | 13657.9% | 1,288 | -9.50 | 1,174 | 1,189 | 1,085 | 778 | 829 | 840 | 823 | 494 | 530 | 621 | 542 | 395 | 281 | 308 | 302 | 284 | 310 | 317 | 290 |
Cashflow From Investing | 100.0% | - | -6.00 | - | - | - | - | - | - | - | - | - | - | - | - | -3.00 | -12.00 | -2.00 | -1.00 | - | 2,347 | 2,690 |
Cashflow From Financing | - | 56,110 | - | - | 15,231 | 47.00 | 17,713 | 126 | 1,381 | 95.00 | 14,928 | 8.00 | 21,438 | 236 | 15,940 | 14,620 | 2,167 | -47.00 | 12,703 | - | - | - |
Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
EXPENSES | ||
Research and development | $ 2,799 | $ 5,534 |
General and administrative | 3,183 | 3,044 |
Total operating expenses | 5,982 | 8,578 |
OTHER INCOME (EXPENSE) | ||
Interest income | 368 | 162 |
Interest expense [note 7] | (813) | (573) |
Change in fair value of contingent consideration [note 5 and note 6] | (52) | |
Other expense | (15) | (3) |
Total other expense | (512) | (414) |
Net loss and comprehensive loss | $ (6,494) | $ (8,992) |
Basic net loss per common share [note 8[d]] | $ (0.26) | $ (0.50) |
Diluted net loss per common share [note 8[d]] | $ (0.26) | $ (0.50) |
Weighted average shares used in computation of basic net loss per common share [note 8[d]] | 25,048,134 | 17,917,769 |
Weighted average shares used in computation of diluted net loss per common share [note 8[d]] | 25,048,134 | 17,917,769 |
Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents [note 6] | $ 66,398 | $ 15,546 |
Grant receivable [note 3] | 111 | |
Prepaid expenses and other assets | 1,311 | 1,325 |
Total current assets | 67,709 | 16,982 |
Right-of-use assets [note 9] | 51 | 66 |
Other assets and restricted cash [note 6] | 94 | 92 |
License agreement [note 4 and note 5] | 1,141 | 1,197 |
Goodwill | 1,034 | 1,034 |
Total assets | 70,029 | 19,371 |
Current liabilities: | ||
Accounts payable | 373 | 618 |
Accrued liabilities other | 1,037 | 351 |
Contingent consideration [note 5 and note 6] | 580 | 528 |
Accrued clinical liabilities | 525 | 280 |
Accrued compensation | 864 | 2,311 |
Current portion of long-term obligations [note 9] | 53 | 63 |
Convertible debt [note 6 and note 7] | 17,141 | 16,662 |
Total current liabilities | 20,573 | 20,813 |
Long-term obligations [note 9] | 6 | |
Total liabilities | 20,573 | 20,819 |
Commitments and contingencies [note 9] | ||
Stockholders' equity: | ||
Common stock, $0.001 par value, 150,000,000 shares authorized, 34,251,911 issued and outstanding at March 31, 2024 and 21,165,760 issued and outstanding at December 31, 2023 | 103 | 90 |
Additional paid-in capital | 221,594 | 164,209 |
Accumulated deficit | (172,245) | (165,751) |
Accumulated other comprehensive income | 4 | 4 |
Total stockholders' equity | 49,456 | (1,448) |
Total liabilities and stockholders' equity | 70,029 | 19,371 |
Series A Convertible Preferred Stock [Member] | ||
Stockholders' equity: | ||
Convertible preferred stock, value | ||
Series B Convertible Preferred Stock [Member] | ||
Stockholders' equity: | ||
Convertible preferred stock, value |